The market outlook for OXLUMO reflects a positive trajectory in both market performance and therapeutic potential for treating primary hyperoxaluria type 1. The drug generated approximately USD 167 ...

The Rubisco-O2 fusion generates a toxic byproduct called glycolate that the plant must then work hard to metabolize and clear from its tissues—an energy-intensive process that diverts resources ...